Mersana Therapeutics Inc (MRSN) - Total Liabilities
Based on the latest financial reports, Mersana Therapeutics Inc (MRSN) has total liabilities worth $122.22 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Mersana Therapeutics Inc - Total Liabilities Trend (2015–2024)
This chart illustrates how Mersana Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. See Mersana Therapeutics Inc (MRSN) liquidity to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Mersana Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Mersana Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Plenitude Bhd
KLSE:5075
|
Malaysia | RM771.64 Million |
|
eCloudvalley Digital Technology Co. Ltd.
TW:6689
|
Taiwan | NT$3.08 Billion |
|
Trada Maritime Tbk
JK:TRAM
|
Indonesia | Rp1.31 Trillion |
|
Namyong Terminal PCL
BK:NYT
|
Thailand | ฿3.28 Billion |
|
Lollands Bank
CO:LOLB
|
Denmark | Dkr4.87 Billion |
|
APM Automotive Holdings Bhd
KLSE:5015
|
Malaysia | RM778.45 Million |
|
Compugen
TA:CGEN
|
Israel | ILA54.02 Million |
Liability Composition Analysis (2015–2024)
This chart breaks down Mersana Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see MRSN stock market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.39 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -2.05 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.95 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Mersana Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Mersana Therapeutics Inc (2015–2024)
The table below shows the annual total liabilities of Mersana Therapeutics Inc from 2015 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $154.17 Million | -18.49% |
| 2023-12-31 | $189.16 Million | -21.93% |
| 2022-12-31 | $242.28 Million | +187.17% |
| 2021-12-31 | $84.37 Million | +86.20% |
| 2020-12-31 | $45.31 Million | +55.06% |
| 2019-12-31 | $29.22 Million | -58.08% |
| 2018-12-31 | $69.71 Million | +14.80% |
| 2017-12-31 | $60.72 Million | -62.22% |
| 2016-12-31 | $160.71 Million | +181.44% |
| 2015-12-31 | $57.10 Million | -- |
About Mersana Therapeutics Inc
Mersana Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops antibody-drug conjugates (ADC) for cancer patients with unmet needs. The company develops Emi-Le (XMT-1660), a B7-H4-targeting Dolasynthen ADC candidate, which is in Phase 1 clinical trial; and XMT-2056, an Immunosynthen ADC targeting a novel human epidermal growth factor receptor 2 that is in Phase 1 clinical trial.… Read more